Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2022-03-09 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
年度股东大会通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2021 Annual General Meeting (AGM) of 普洛药业股份有限公司. It includes details about the meeting time, location, agenda items (including approval of the 2021 annual report, board reports, financial statements, profit distribution plan, and other proposals), voting procedures, and proxy forms. The document does not contain the actual annual report or financial statements but rather informs shareholders about the meeting and the items to be voted on. The document length is 4153 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-03-09 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 8th Board of Directors of 普洛药业股份有限公司. It includes voting results on various agenda items such as approval of the 2021 Annual Report, Board Work Report, General Manager Work Report, Financial Statements, Internal Control Evaluation Report, Profit Distribution Plan, and other governance-related proposals. It also mentions the nomination and election of an independent director and amendments to company bylaws and rules. The document is not the annual report itself but a formal announcement of board meeting decisions that will be submitted to the shareholders' meeting for approval. The document length is 2617 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Board/Management Information (MANG), as it primarily concerns board meeting resolutions and management decisions.
2022-03-09 Chinese
关于对公司第一期员工持股计划存续期展期事项发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the company's independent directors regarding the extension of the duration of the company's first employee stock ownership plan. It discusses compliance with relevant regulations and the board's voting procedures. The document is short (367 characters) and focuses on governance and compliance related to employee stock plans, not financial results or detailed reports. It is not an annual report, audit report, earnings release, or any financial statement. It is also not a voting result announcement or a proxy solicitation. The content fits best under Board/Management Information (MANG) as it relates to board-level decisions and opinions on management matters.
2022-03-09 Chinese
关于对拟续聘会计师事务所发表的独立意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding the proposed reappointment of an audit firm for the company's 2022 annual audit. It references regulatory rules related to independent directors and audit firm appointment. The content is an opinion on the audit firm reappointment, not the audit report itself. The document is short (381 characters) and does not contain financial statements or audit results. Therefore, it is best classified as an Audit Report / Information (AR) since it relates to audit matters but is not a full annual report or audit report itself. Confidence is high due to clear context and content. FY 2022
2022-03-09 Chinese
2021年度独立董事述职报告（陈凌）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2021" from a company. It details the independent director's attendance at board meetings, opinions on various company matters, committee work, and efforts to protect investor rights during the 2021 fiscal year. The content focuses on governance, board activities, and compliance with laws and regulations related to board duties. It does not contain financial statements or audit results, nor is it an announcement or presentation. This type of document fits best under Board/Management Information (MANG), as it relates to the activities and reports of a board member rather than a full annual report or audit report.
2022-03-09 Chinese
内幕信息知情人登记管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '内幕信息知情人登记管理制度' (Insider Information Insider Registration Management System) for 普洛药业股份有限公司. It outlines the management, registration, confidentiality, and responsibilities related to insider information within the company. It references relevant laws and regulations, describes procedures for insider information registration, confidentiality agreements, and responsibilities for insider trading prevention. There are no financial statements, earnings data, or report summaries. The document is a governance and compliance policy related to insider information management rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2022-03-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.